Literature DB >> 35186683

Clinical research of EX-PRESS drainage device and modified trabeculectomy combined with intravitreal conbercept treatment for neovascular glaucoma.

Peng Li1,2, Qing Liu1, Xiao-Min Liu1, Li Wang3, Zhao-Jiang Du4, Qian-Yan Kang2.   

Abstract

AIM: To evaluate the efficacy and safety of modified trabeculectomy (experimental group) and implantation of EX-PRESS drainage device (control group), combined with intravitreal conbercept injection for neovascular glaucoma (NVG).
METHODS: Totally 30 patients with NVG were selected from June 2014 to June 2017, and randomly divided into experimental group and control group. All patients were underwent intravitreal conbercept (0.5 mg/0.05 mL) treatment before surgery. Modified trabeculectomy was performed in MT group, while EX-PRESS drainage device implantation was performed in EX group. The success rates, best corrected visual acuity (BCVA), intraocular pressure (IOP), filtering bleb and complications were observed and compared.
RESULTS: The differences of success rate, BCVA and filtering bleb were not statistically significant 12mo after the surgery (P>0.05), however, the difference of IOP at 1d, 1wk, 1, 3, and 6mo after surgery was statistically significant (F time=390.64, P time<0.0001) between two groups. The interactions between two groups in the given time showed no significant difference (F intergroup×time=0.181, P intergroup×time=0.57), and also there was no significant difference in IOP between the two groups (F=3.16, P=0.09). The results of pairwise comparison at each time point showed no significant difference in IOP between 1d and 1wk, 3 and 6, 3mo and 12mo after surgery (P>0.05), while the results at other time point indicate statistical differences (P<0.05).
CONCLUSION: The modified trabeculectomy and the implantation of EX-PRESS drainage device have clinical application value in reducing IOP and postoperative complications of refractory NVG. International Journal of Ophthalmology Press.

Entities:  

Keywords:  EX-PRESS; conbercept; modified trabeculectomy; neovascular glaucoma

Year:  2022        PMID: 35186683      PMCID: PMC8818451          DOI: 10.18240/ijo.2022.02.08

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  17 in total

Review 1.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-02

2.  The effects of vitreous on proliferative diabetic retinopathy and the response to pan retinal photocoagulation.

Authors:  J Sebag; Jeannie Nguyen-Cuu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-22       Impact factor: 3.117

3.  Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial.

Authors:  Homayoun Nikkhah; Hossein Ghazi; Mohammad Reza Razzaghi; Saeed Karimi; Alireza Ramezani; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2017-02-06       Impact factor: 2.031

4.  Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions.

Authors:  Thomas J Wubben; Mark W Johnson
Journal:  Am J Ophthalmol       Date:  2019-03-13       Impact factor: 5.258

Review 5.  Long-term outcomes and risk factors for failure with the EX-press glaucoma drainage device.

Authors:  C Mariotti; E Dahan; M Nicolai; L Levitz; S Bouee
Journal:  Eye (Lond)       Date:  2013-11-15       Impact factor: 3.775

Review 6.  Neovascular Glaucoma.

Authors:  Shane J Havens; Vikas Gulati
Journal:  Dev Ophthalmol       Date:  2015-10-26

Review 7.  Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.

Authors:  Vanessa Andrés-Guerrero; Lucía Perucho-González; Julián García-Feijoo; Laura Morales-Fernández; Federico Saenz-Francés; Rocío Herrero-Vanrell; Luis Pablo Júlvez; Vicente Polo Llorens; José María Martínez-de-la-Casa; Anastasios-Georgios Konstas
Journal:  Adv Ther       Date:  2016-12-20       Impact factor: 3.845

8.  Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.

Authors:  Yaoyao Sun; Yong Liang; Peng Zhou; Huijuan Wu; Xianru Hou; Zeqin Ren; Xiaoxin Li; Mingwei Zhao
Journal:  BMC Ophthalmol       Date:  2016-08-30       Impact factor: 2.209

9.  Comparison of the safety and efficacy of triple sequential therapy and transscleral cyclophotocoagulation for neovascular glaucoma in the angle-closure stage.

Authors:  Ying Hong; Yuntao Hu; Hongliang Dou; Changguan Wang; Chun Zhang; Zhizhong Ma
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

10.  Ahmed Valves vs Trabeculectomy Combined with Pans Plana Vitrectomy for Neovascular Glaucoma with Vitreous Hemorrhage.

Authors:  Menghua H Wang; Qiuming M Li; Hongtao T Dong; Shuqian Q Dong; Yang Li; Chunyan Y Zheng
Journal:  Eur J Ophthalmol       Date:  2017-11-08       Impact factor: 2.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.